GLP-1semaglutideliraglutidecardiovascularreal-world evidence

Letter questions semaglutide versus liraglutide target trial emulation

Correspondence in the British Journal of Clinical Pharmacology responds to a real-world comparison of the two GLP-1 agonists on diabetes and cardiovascular outcomes.

By Maren Holt · Senior Reporter, GLP-1

Oct 8 20:00 ETSource: British journal of clinical pharmacology

The wire

01The British Journal of Clinical Pharmacology published a comment on a target trial emulation comparing semaglutide and liraglutide for incidence of diabetes and cardiovascular disease.
02Clinicians weighing GLP-1 choices on real-world evidence should watch how methodological critiques of emulation studies land in the peer-reviewed record.
03Only the correspondence title is available; the specific objections raised and any authors' reply are not detailed here.

From the source

Comment on 'Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data'
British journal of clinical pharmacology · 2026 Oct 9 · Choudhry MA et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42855911/